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Abstract
Background: Treatment options for advanced thyroid cancer refractory to standard therapies are limited. The safety
and efficacy of pembrolizumab were evaluated in patients with advanced differentiated thyroid cancer expressing
programmed death ligand 1 (PD-L1).
Methods: Patients with advanced thyroid cancer were enrolled in the nonrandomized, phase Ib KEYNOTE-028 trial
conducted to evaluate safety and antitumor activity of the anti–programmed death 1 (PD-1) antibody pembrolizumab
in advanced solid tumors. Key eligibility criteria were advanced papillary or follicular thyroid cancer, failure of standard
therapy, and PD-L1 expression in tumor or stroma cells (assessed by immunohistochemistry). Pembrolizumab 10mg/kg
was administered every 2 weeks up to 24months or until confirmed progression or intolerable toxicity. The primary
endpoint was objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors, version 1.1.
Results: Twenty-two patients were enrolled: median age was 61 years; 59% were women; and 68% had papillary
carcinoma. Median follow-up was 31months (range, 7–34months). Treatment-related adverse events were observed in
18 (82%) patients; those occurring in ≥15% of patients were diarrhea (n = 7) and fatigue (n = 4). One grade ≥ 3 treatment-
related adverse event occurred (colitis, grade 3); no treatment-related discontinuations or deaths occurred. Two patients
had confirmed partial response, for an ORR of 9% (95% confidence interval [CI], 1–29%); response duration was 8 and 20
months. Median progression-free survival was 7months (95% CI, 2–14months); median overall survival was not reached
(95% CI, 22months to not reached).
Conclusions: Results of this phase Ib proof-of-concept study suggest that pembrolizumab has a manageable safety
profile and demonstrate evidence of antitumor activity in advanced differentiated thyroid cancer in a minority of patients
treated. Further analyses are necessary to confirm these findings.
Trial registration: Clinicaltrials.gov identifier: NCT02054806. Registered 4 February 2014.
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Background
Thyroid cancer is the most common endocrine malig-
nancy and the eighth most common cancer in the United
States [1, 2]. Although the prognosis for most thyroid
cancers is generally good (98% overall 5-year survival rate)
[2], approximately 10% of patients with differentiated thy-
roid cancer develop progressive invasive primary disease,
5% develop distant metastases, and 20–30% experience
disease recurrence [3].
Metastatic disease is usually treated with a combination
of surgery and radioiodine ablation (RAI), and success
depends on whether metastasis is in a location amenable
to surgical resection or radioiodine uptake in the tumor
tissue is significant [1, 4]. Since the identification of mul-
tiple kinase inhibitors (MKIs), more treatment options for
recurrent/metastatic thyroid cancer are available [5]. Two
MKIs—sorafenib [6, 7] and lenvatinib [8, 9]—have been
approved in many countries for treatment of advanced
differentiated thyroid cancer. Results of a phase III ran-
domized trial revealed a progression-free survival (PFS)
benefit with sorafenib compared with placebo in patients
with RAI-refractory, advanced, differentiated thyroid
cancer [10]. Additionally, lenvatinib was also associated
with significant improvement in PFS and objective re-
sponse rate (ORR) compared with placebo; median overall
survival (OS) was not reached after a median follow-up of
17months. Lenvatinib was associated with considerable
treatment-related toxicity, with a drug-related mortality
rate of 2% [11]. Sorafenib and lenvatinib are now rec-
ommended by the National Comprehensive Cancer
Network for the treatment of progressive, RAI-refractory
differentiated thyroid carcinoma [4]. However, despite
being effective, their duration of response is limited, and
disease ultimately progresses. Therefore, new therapies are
needed.
The development and approval of immunotherapeutics
for cancer, and immune checkpoint inhibitors such as
anti–CTLA-4 and anti–programmed death 1 (PD-1)
agents in particular, have altered the treatment landscape
for many malignancies [12]. They act to re-establish im-
mune surveillance, from which some cancers are able to
hide [12, 13]. The clinical benefit observed with immune
checkpoint inhibitors varies with both the immunothera-
peutic agent and the type of cancer. However, PD-1
blockade appears to be effective for a wide variety of
tumor types [12]. Thyroid cancer cells are known to pro-
duce cytokines and chemokines that are able to promote
tumorigenesis. In aggressive, recurrent papillary thyroid
cancer, the frequency of regulatory T cells is increased,
and expression of PD-1 ligand 1 (PD-L1) is correlated
with greater risk of recurrence and reduced disease-free
survival [12]. Targeting of these immune system compo-
nents may thus prove useful in the treatment of thyroid
cancer. The application of immune checkpoint inhibitors
in advanced thyroid cancer has not been well studied
to date.
The PD-1 immune checkpoint pathway regulates induc-
tion and maintenance of peripheral immune tolerance via
engagement between the PD-1 receptor (expressed on
monocytes and T, B, and natural killer cells) and its ligands
PD-L1 and PD-L2 [14]. Upregulation of this pathway in-
duces suppression of immune response in many tumors,
allowing them to escape immune surveillance [15, 16].
Expression of PD-L1 in advanced differentiated thyroid
carcinomas, when detected, has been associated with
aggressive disease and poor prognosis, making anti–PD-1
therapy a potential treatment option [3, 17, 18].
Pembrolizumab is a fully humanized, selective immuno-
globulin G4/κ anti–PD-1 monoclonal antibody that ex-
hibits antitumor activity by blocking interaction between
PD-1 and its ligands. It has been found to be effective in
head and neck cancers [19–21]. Pembrolizumab has
demonstrated robust antitumor activity and a favorable
safety profile in multiple tumor types, and it is currently
approved in more than 60 countries for one or more ad-
vanced malignancies.
The aim of this study was to assess the safety, tolerability,
and antitumor activity of pembrolizumab in patients with
PD-L1–positive, advanced thyroid cancer who were en-
rolled in the phase Ib KEYNOTE-028 trial.
Methods
Study design and patients
Eligibility criteria were age ≥ 18 years; presence of cyto-
logically or histologically confirmed, PD-L1–positive, lo-
cally advanced or metastatic follicular or papillary thyroid
cancer in which, per the opinion of the treating physician,
previous standard therapy was ineffective, did not occur,
or was not considered appropriate; measurable disease
based on Response Evaluation Criteria In Solid Tumors,
version 1.1 (RECIST v1.1); Eastern Cooperative Oncology
Group (ECOG) performance status 0 or 1; and adequate
organ function. Patients were not required to be radio-
active iodine refractory in order to be enrolled in the
study. Exclusion criteria were current or past participation
in a study of an investigational agent or investigational
device ≤4 weeks before the first dose of treatment; prior
anticancer monoclonal antibody therapy ≤4 weeks before
the first pembrolizumab dose; immunosuppressive ther-
apy or diagnosis of immunodeficiency therapy ≤7 days
before the first pembrolizumab dose; chemotherapy, tar-
geted small-molecule therapy, or radiation therapy ≤2
weeks before the first pembrolizumab dose; therapy with
any anti–PD-1, anti–PD-L1, or immune checkpoint in-
hibitor; active autoimmune disease that necessitated
systemic treatment in the preceding 2 years; interstitial
lung disease; known additional malignancy that was
progressing or necessitated treatment; and active brain
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metastases. The study protocol and all amendments
were approved by the institutional review board or ethics
committee of each participating site and were conducted
per the principles expressed in the Declaration of Helsinki.
All patients provided written informed consent to partici-
pate. This trial was registered with Clinicaltrials.gov, iden-
tifier NCT02054806.
Treatment and assessments
Pembrolizumab 10 mg/kg was administered every 2
weeks via 30-min infusion. Treatment continued for 24
months or until confirmed progressive disease, unacceptable
adverse events (AEs), or investigator or patient decision to
withdraw. Dosing was interrupted because of unacceptable
toxicity but could resume after resolution of toxicity to
grade 0/1 within 12weeks of the last infusion. Response was
assessed by computed tomography or magnetic resonance
imaging every 8 weeks for the first 6months and every 12
weeks thereafter. Patients who discontinued pembrolizumab
after substantiated complete response (CR) after ≥24weeks
of therapy and ≥ 2 treatments after initial CR, or who dis-
continued after receiving pembrolizumab for ≥24months
for reasons other than progressive disease or unacceptable
toxicity could be eligible for up to 1 year of re-treatment
after substantiation by radiographic progressive disease.
Patients were permitted to continue to treatment after the
onset of progressive disease if the patient’s condition was
clinically stable in the investigator’s judgment. AEs
were graded per the National Cancer Institute Com-
mon Terminology Criteria for Adverse Events, version
4.0, and were monitored throughout the study and for
30 days after treatment discontinuation (90 days for ser-
ious AEs). Immune-mediated AEs were also reported and
were defined as events with potentially drug-related im-
munologic causes that were consistent with an immune
phenomenon, regardless of whether they were attributable
to the study drug or to an immune response.
Tumor PD-L1 status was determined at a central la-
boratory during the screening period using either an ar-
chived formalin-fixed, paraffin-embedded tumor sample
or a newly obtained biopsy sample. PD-L1 expression was
assessed using a prototype immunohistochemistry assay
(QualTek Molecular Laboratories, Goleta, California) [22]
and the 22C3 antibody (Merck & Co., Inc., Kenilworth,
New Jersey). PD-L1 positivity was defined as membranous
Table 1 Baseline demographics and clinical characteristics
Characteristic, n (%)a N = 22
Median age, years (range) 61 (23–76)
Sex
Male 9 (41)
Female 13 (59)
Race
Asian 7 (32)
Multiracial 1 (5)
White 14 (64)
ECOG PS
0 12 (55)
1 10 (45)
Thyroid cancer histology
Papillary 15 (68)
Follicular 7 (32)
Treatment-naiveb
Yes 6 (27)
No 16 (73)
Prior lines of therapy for advanced disease
1 7 (32)
2 5 (23)
3 3 (14)
4 1 (5)
Unknown 6 (27)
Select prior therapiesc
Iodine 18 (82)
Sorafenib 7 (32)
Pazopanib 3 (14)
Lenalidomide 2 (9)
Cediranib 2 (9)
Vemurafenib 2 (9)
Sunitinib 2 (9)
Everolimus 2 (9)
Paclitaxel 2 (9)
ECOG PS Eastern Cooperative Oncology Group performance status
aTotals may equal > 100% because of rounding
bPatients had received no prior oncologic or biologic drugs but may have
received iodine radiotherapy or surgery
cPatients may have received more than 1 prior treatment listed
Table 2 Treatment-related adverse events: all grades occurring
in ≥2 patients and grade 3-5a occurring in any patient
Treatment-related adverse events
(N = 22)
All grades
n (%)
Grade 3-5a
n (%)
All 18 (82) 1 (5)
Diarrhea 7 (32) 0
Fatigue 4 (18) 0
Pruritus 3 (14) 0
Rash 3 (14) 0
Decreased appetite 2 (9) 0
Headache 2 (9) 0
Cough 2 (9) 0
Pneumonitis 2 (9) 0
Colitis 1 (5) 1 (5)
aThere were no grade 4 or 5 treatment-related adverse events
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staining on ≥1% modified proportion score or interface
pattern as described previously [22]. Note that tumor
markers and laboratory evaluations specific for thyroid
cancer were not required to be captured by investigators
because of the signal-finding nature of the study.
Endpoints
Primary endpoints were ORR, defined as the proportion
of patients with a best overall response of confirmed CR
or partial response (PR) per RECIST v1.1 by investigator
review, and safety and tolerability. Secondary endpoints
were PFS (time from enrollment to the first documented
occurrence of PD per RECIST v1.1 or death from any
cause, whichever occurred first), OS (time from enroll-
ment to death from any cause), and duration of response
(time from first RECIST v1.1–based response to progres-
sive disease in patients who experience PR or better).
Statistical analyses
The binomial exact method was used for power and
sample size calculations. A sample size of 22 evaluable
patients in this cohort was calculated to provide 80%
power to demonstrate that the best ORR exceeded 10% at
an overall one-sided 8% α level if the true best ORR was
35%. The efficacy population was composed of all patients
who received ≥1 dose of pembrolizumab and had measur-
able disease at baseline per RECIST v1.1. The safety popu-
lation was composed of all patients who received ≥1 dose
of pembrolizumab. A truncated sequential probability test
was used to evaluate ORR; PFS, OS, and duration of re-
sponse were estimated using the Kaplan-Meier method.
The data cutoff was February 20, 2017.
Results
Patient baseline characteristics and treatment
Fifty-one patients with thyroid cancer were screened; of 36
(71%) with PD-L1–positive tumors, 22 were enrolled (per
eligibility criteria) and received ≥1 dose of pembrolizumab.
Fig. 1 Duration of exposure to pembrolizumab and summary of best overall response (N = 22) aPatient was considered clinically stable per
investigator’s judgment and was permitted to continue treatment after progressive disease
Table 3 Antitumor activity
Response evaluation (N = 22) n % (95% CI) or
median (range)
ORRa,b, % (95% CI) 2 9 (1–29)
CR 0 0 (0–15)
PR 2 9 (1–29)
SD 13 59 (36–79)
PD 7 32 (14–55)
CBRb, % (95% CI) 11 50 (28–72)
SD ≥6 months, % (95% CI) 9 69 (39–91)
TTR (months), median (range) 2 5 (4–5)
DOR (months), median (range) 2 14 (8–20)
Follow-up duration (months), median (range) 22 31 (7–34)
Abbreviations: CBR clinical benefit rate, CR complete response, DOR duration
of response; NR not reached, ORR objective response rate, PD progressive
disease, PR partial response, SD stable disease, TTR time to response
aORR = CR + PR
bConfirmed by investigator review
cCBR = CR + PR + SD ≥6 months
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Baseline characteristics are listed in Table 1; median age
was 61 years (range, 23–76 years); 13 (59%) were women;
and 12 (55%) had an Eastern Cooperative Oncology
Group (ECOG) performance status of 0. Relative propor-
tions of patients with papillary and follicular thyroid can-
cer were approximately 2:1 (papillary, 68%; follicular,
32%). Nine (41%) patients had ≥2 prior lines of therapy for
advanced disease; 11 (50%) patients had previously re-
ceived an MKI. The most frequent prior treatment was
RAI (18 patients [82%]), followed by sorafenib (7 [32%])
and pazopanib (3 [14%]). Among the 22 PD-L1–positive
patients enrolled in this cohort, 20 (91%) were PD-L1
positive in the tumor only and 2 (9%) were positive in the
tumor and the stroma.
Median follow-up was 31months (range, 7–34months).
At the data cutoff date, 18 patients (82%) had discontinued
the study: 10 because of PD, 7 because of patient or phys-
ician decision, and 1 was lost to follow-up; 4 remained on
study.
Safety
Eighteen patients (82%) experienced treatment-related
AEs, most commonly diarrhea (7 [32%]), fatigue (4
[18%]), pruritus (3 [14%]), and rash (3 [14%]); all but 1
were grade 1 or 2 (Table 2). No grade 4 treatment-re-
lated AEs or treatment-related deaths or discontinua-
tions occurred. Immune-mediated AEs were reported
in 5 patients: pneumonitis (2 patients, 1 each of grades
1 and 2), interstitial lung disease (1 patient, grade 1),
colitis (1 patient, grade 3), and hypothyroidism (1 pa-
tient, grade 2).
a
b
Fig. 2 a Change from baseline in sum of longest diameters of target lesions (n = 21) and (b) change from baseline over time (n = 21)
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Antitumor activity
Confirmed PR (by investigator review) was observed in 2
patients, for an ORR of 9% (95% confidence interval
[CI], 1–29%) (Table 3). Time to response for the 2 pa-
tients with substantiated PR were 4 and 5months, re-
spectively, with response durations of 20 and 8months,
respectively (Fig. 1). Both patients had papillary thyroid
cancer. Stable disease (SD) was experienced by 13 pa-
tients (59%; 95% CI, 36–79%), with a median duration of
7 months yielding a disease control rate (i.e. confirmed
PR + SD) of 68%. SD was achieved by 57% (4/7) of pa-
tients with follicular histology and 60% (9/15) of patients
with papillary histology. The clinical benefit rate (i.e.
confirmed PR + SD ≥6 months) was 50% (95% CI, 28–
72%). Seven patients had progressive disease as best re-
sponse (32%; 95% CI, 14–55%). Of these, 3 patients had
follicular cancer and 4 patients had papillary thyroid
cancer, representing 43 and 27% of the respective histo-
logic subgroups. Reduction in tumor size (sum of the
longest diameter) from baseline was observed in 15
(68%) of 22 patients in whom this parameter was evalu-
able and was generally maintained (Fig. 2).
Median PFS was 7 months (95% CI, 2–14months),
and 6- and 12-month PFS rates were 59 and 36%,
a
b
Fig. 3 Kaplan-Meier estimates (N = 22) of (a) PFS and (b) OS
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respectively. Median OS was not reached (95% CI, 22
months to not reached), with 6- and 12-month OS rates
of 100 and 90%, respectively (Fig. 3).
Discussion
Until recently, treatment options for advanced differenti-
ated thyroid carcinomas were limited to surgery and
RAI [4]. The recent approval of MKIs has improved the
therapeutic arsenal, benefiting those whose tumors pro-
gress after RAI or for whom surgery is contraindicated.
Nonetheless, disease in patients treated with approved
agents will inevitably progress. Because thyroid cancer is
a relatively common disease with a high unmet medical
need in refractory patients, pembrolizumab was evalu-
ated in a thyroid cancer cohort of KEYNOTE-028. In
this phase Ib, proof-of-concept study, pembrolizumab
was well tolerated in patients with advanced papillary or
follicular thyroid cancer that had progressed with stand-
ard therapy, and no treatment-related discontinuations
or deaths occurred. The safety profile was generally con-
sistent with that observed previously for pembrolizumab
[19, 20]. After a median follow-up of 31 months, con-
firmed ORR was 9%, disease control rate was 68%, and
clinical benefit rate was 50%. Two patients had con-
firmed PR, and, in 13 other patients, median duration of
SD was 7 months. Median PFS was 7 months and, al-
though median OS was not reached at the data cutoff date,
6- and 12-month OS rates were high at 100 and 90%,
respectively. Although PFS data in this study were greater
than those of placebo-treated patients with RAI-refractory,
differentiated thyroid cancer whose disease progressed after
previous treatment (4–6months) [10, 11], patients in
KEYNOTE-028 were not required to have experienced dis-
ease progression with their previous treatment before study
entry. These results must also be interpreted considering
the biological behavior of advanced thyroid cancer, which is
known to often have an indolent course. In addition, pa-
tients in KEYNOTE-028 were heavily pretreated; therefore,
it is unclear what the PFS for this group would have been
without treatment or how the effects of multiple prior ther-
apies may confound these results. Nonetheless, objective
responses were observed in a minority of patients treated.
Hence, the observed response rates and PFS differences
must be substantiated in subsequent clinical trials.
PD-L1 expression has been observed in differentiated thy-
roid tumors, including the papillary subtype. In one study,
59% (13/22) of differentiated thyroid tumors expressed
PD-L1, and 50% of tumors contained PD-1–positive lym-
phocytes [18]. In another retrospective analysis, membran-
ous PD-L1 expression was observed in 40% (74/185) of all
surgically resected papillary thyroid tumors analyzed
and in > 70% (53/74) of advanced-stage (III/IV) tumors
[3]. In that study, the presence of PD-L1 staining was
associated with significantly reduced disease-free survival
[3]. The high membranous PD-L1 expression found in
advanced-stage tumors suggests that, as in other PD-L1–
expressing tumors, pembrolizumab could be an effective
therapy for papillary and follicular thyroid cancer. How-
ever, archival tissue was permitted in this study and, in
some cases, was taken from metastatic sites. In thyroid
cancer, this can be a significant limitation because tumor
dedifferentiation with progression is a frequent feature
[23]. Therefore, the treated lesions may not represent dif-
ferentiated thyroid carcinoma. Future investigation that
requires fresh biopsy specimens taken immediately before
therapy, when clinically feasible, may be informative.
Given that KEYNOTE-028 was a signal-finding study,
two additional limitations, among others, that might
have affected the generalizability of the results were that
patients were not required to be iodine refractory before
enrollment and that tumor marker and laboratory evalu-
ations were not required to be collected, despite the fact
that these items are specific to thyroid cancer. Add-
itional studies that include these items will be needed to
further confirm findings.
Conclusion
Results of this proof-of-concept study suggest that pem-
brolizumab may be effective and have a favorable safety
profile in PD-L1–positive thyroid cancer. These data may
lay the foundation for further clinical evaluation of pem-
brolizumab to establish its place in the differentiated thy-
roid carcinoma therapeutic arena. Clinical benefit of a
fixed dose of pembrolizumab (200mg once every 3 weeks)
in advanced differentiated thyroid cancer will be further
investigated in the multicohort phase 2 KEYNOTE-158
trial (Clinicaltrials.gov identifier: NCT02628067).
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